Update in Basal Insulins: Your Questions Answered

Saturday, September 12, 2015; 6:15–7:15 AM EST
Intercontinental Miami Hotel, Grand Ballroom

This course is a live CME-certified ancillary symposium presented at CEU 2015, the 67th Clinical Endocrinology Update Meeting, held in Miami, Florida, September 10–12, 2015. CEU 2015 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).

This activity is supported by an educational grant from sanofi-aventis U.S. Inc.


Welcome and Introduction
Andrew J. Ahmann, MD


  • Overview of benefits and challenges of insulin initiation
  • Newly approved insulin glargine U-300 (concentrated basal insulin)
  • Emerging PEGylated insulin lispro (LY2605541)
  • Emerging insulin degludec (ultra-long-acting insulin)
  • Head-to-head summary

Question Review and Clinical Case Presentation

Audience Q&A and Closing Remarks

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Evaluate the benefits of initiating insulin therapy and summarize common barriers to basal insulin therapy
  • Summarize benefits and limitations of new and emerging basal insulins
  • Select among basal insulin and non-insulin therapies to improve glycemic outcomes and minimize adverse effects taking individual patient contexts into consideration

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
Course expires: 
Intercontinental Miami Hotel
Miami, FL
United States

Andrew J. Ahmann, MD
Professor of Medicine
Director, Harold Schnitzer Diabetes Health Center
Oregon Health & Science University
Portland, Oregon


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Andrew J. Ahmann, MD: Consultant, Lilly, Sanofi; Research Grant Support, Novo Nordisk

The following SPC member who reviewed content for this activity reported relevant financial relationships: Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation